Biotech Values

[DewDiligence]

Perhaps I'm being unduly harsh but do you see a lot of long-term upside for another RA monoclonal antibody that's just in mid-stage testing given the existing RA monoclonal antibodies on the market, the other ones in development, and the prospect of the oral RA pills and generic RA biologics to come?

If a drug could have TNF-alpha-like efficacy and significantly better safety/tolerability, it would have the potential to be a colossal blockbuster. This is presumably what ABT has in mind.